The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus

Coronary Artery Disease

Volumn 12, Issue 5, 2001, Pages 413-423

  Rosenblatt, Sidney ^a   Miskin, Barry ^b   Glazer, N Bradly ^c   Prince, Melvin J ^d   Robertson, Kenneth E ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Palm Beach Esthetic Center   (United States)

^c TAKEDA PHARMACEUTICALS   (United States)

^d ELI LILLY AND COMPANY   (United States)

Author keywords

C peptide; Fasting insulin; Fasting plasma glucose; HbA1c; HDL C; LDL C; Pioglitazone; Thiazolidinediones; Triglycerides; Type 2 diabetes mellitus

Indexed keywords

C PEPTIDE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; PIOGLITAZONE; PLACEBO; THIAZOLIDINE DERIVATIVE; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; ATHEROGENESIS; BLOOD GLUCOSE MONITORING; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; DYSLIPIDEMIA; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

ADULT; AGED; ARTERIOSCLEROSIS; BLOOD GLUCOSE; C-PEPTIDE; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; ENDPOINT DETERMINATION; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERLIPIDEMIAS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; ISLETS OF LANGERHANS; LIPIDS; LIPOPROTEINS; MALE; MIDDLE AGED; SINGLE-BLIND METHOD; THIAZOLES; THIAZOLIDINEDIONES; TREATMENT OUTCOME; UNITED STATES;

EID: 0034919411     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019501-200108000-00011     Document Type: Article

References (66)

1. Prevalence of diabetes, impaired fasting glucose and impaired glucose tolerance in US adults
2. National Institute of Diabetes, and Digestive and Kidney Diseases
3. Diabetes and atherosclerosis; an epidemiological view
4. Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarction
5. Mortality in non-insulin-dependent diabetes
6. Mortality in adults with and without diabetes in a national cohort of the US population, 1971-1993
7. Lipids, diabetes, and coronary heart disease: Insights from the Framingham Study
8. Diabetes and cardiovascular disease: A statement for healthcare professionals from the American Heart Association
9. UK Prospective Diabetes Study: IV Characteristics of newly presenting type 2 diabetic patients: Male preponderance and obesity at different ages
10. Hyperlipidemia in diabetes
11. UK Prospective Diabetes Study 27: Plasma lipids, Effects of age and gender
12. The pathophysiology and treatment of lipid disorders in diabetes mellitus
13. Relationship between blood glucose level and mortality in patients with NIDDM. The Munich general practitioner project
14. Ten-year cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein composition in type 2 (non-insulin-dependent) diabetic and non-diabetic subjects
15. Effects of diabetes and level of glycaemia on all-cause and cardiovascular mortality
16. NIDDM and its metabolic control predict coronary heart disease in elderly subjects
17. 1c with prevalent cardiovascular disease in the original cohort of the Framingham Heart Study
18. The triumvirate: β-cell, muscle, liver: A collusion responsible for NIDDM
19. Insulin sensitivity and acute insulin response in African American non-Hispanic whites and Hispanic subjects with NIDDM: The insulin resistance atherosclerosis study
20. Plasma insulin as coronary heart disease risk factor: Relationship to other risk factors and predictive value during 9 1/2 year follow-up on the Helsinki Policemen Study Population
21. Coronary heart disease incidence and cardiovascular mortality in Brusselton with reference to glucose and insulin concentration
22. Hyperinsulinaemia as a predictor of coronary heart disease mortality in a healthy population: The Paris Prospective Study, 15-year follow-up
23. Insulin sensitivity in subjects with type 2 diabetes. Relationship to cardiovascular risk factors: The Insulin Resistance Atherosclerosis Study
24. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes
25. Pioglitazone (AD-4833) ameliorates insulin resistance in patients with NIDDM. AD-4833 Glucose Clamp Study Group, Japan Tohoku
26. Pioglitazone enhances splanchnic glucose uptake as well as peripheral glucose uptake in non-insulin-dependent diabetes mellitus. AD-4833 Clamp-OGL. Study Group
27. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge
28. Homeostasis model assessment: Insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man
29. The homeostasis model in the San Antonio Heart Study
30. Homeostasis model assessment as a clinical index of insulin resistance in type 2 diabetic patients treated with sulfonylureas
31. Insulin sensitivity and its measurement: Structural commonalities among the methods
32. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
33. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study
34. Pioglitazone increases insulin sensitivity, reduces blood glucose, insulin, and lipid levels, and lowers blood pressure, in obese, insulin-resistant rhesus monkeys
35. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: A subgroup analysis of the Scandinavian simvastatin survival study (4S)
36. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
37. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease
38. High-density lipoprotein - The clinical implications of recent studies
39. Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality: A 21-year follow-up of 8000 men
40. Dyslipidemia and hyperglycemia predict coronary heart disease events in middle-aged patients with NIDDM
41. Preoperative triglycerides predict post-coronary artery bypass graft survival in diabetic patients
42. Gemfibrozil for secondary prevention of coronary heart disease in men with low levels of HDL cholesterol
43. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease
44. Troglitazone has a reducing effect on thromboxane production
45. Troglitazone reduces reactive oxygen species generation by leukocytes and lipid peroxidation and improves flow-mediated vasodilatation in obese subjects
46. Thiazolidinediones down-regulate plasminogen activator inhibitor type 1 expression in human vascular endothelial cells: A possible role for PPARγ in endothelial function
47. Thiazolidinediones suppress endothelin-1 secretion from bovine vascular endothelial cells: A new possible role of PPARγ on vascular endothelial function
48. Pioglitazone attenuates hypertension and inhibits growth of renal arteriolar smooth muscle in rats
49. Differential inhibitory effects of antidiabetic drugs on arterial smooth muscle cell proliferation
50. Effects of troglitazone and pioglitazone on cytokine-mediated endothelial cell proliferation in vitro
51. Troglitazone inhibits mitogenic signaling by insulin in vascular smooth muscle cells
52. Pioglitazone suppresses neointimal thickening by its inhibitory effect on vascular smooth muscle cell growth via a MEK-ERK coupling with Pyk2
53. Pioglitazone reduces smooth muscle cell density of rat carotid arterial intima induced by balloon catheterization
54. Effects of thiazolidinediones on growth and differentiation of human aorta and coronary myocytes
55. 1-adrenoreceptor-induced DNA synthesis in vascular smooth muscle cells
56. Troglitazone induces apoptosis via the p53 and Gadd45 pathway in vascular smooth muscle cells
57. Attenuation of hypertension by insulin-sensitizing agents
58. Clinical evaluation of an insulin-resistance improving agent, AD-4833, in patients with non-insulin-dependent diabetes mellitus (NIDDM) on diet therapy alone: A placebo-controlled, double-blind clinical study
59. Dose finding study of AD-4833 in patients with NIDDM on diet therapy alone: Double-blind comparative study on four dosages
60. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in patients with type 2 diabetes mellitus (T2DM)
61. Troglitazone reduces LDL. Oxidation and lowers plasma E-selectin concentration in NIDDM patients
62. Effects of troglitazone on frequency of coronary artery vasospastic-induced angina pectoris in patients with diabetes mellitus
63. Potent inhibitory effect of troglitazone on arterial wall thickness in type 2 diabetes
64. Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus: A serial intravascular ultrasound study
65. Thiazolidinediones